Natco Pharma

Natco Pharma
Company type
Public
NSE: NATCOPHARM
BSE: 524816
IndustryPharmaceuticals
Founded1981
FounderVC Nannapaneni
Headquarters
Hyderabad, Telangana
,
India
Area served
Global
Key people
VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2]
RevenueIncrease ₹4,784 crore (US$500 million) (2025)
Increase ₹2,550 crore (US$270 million) (2025)
Increase ₹1,883 crore (US$200 million) (2025)
Websitenatcopharma.co.in
Footnotes / references
Financials as of 31 March 2025.[3]

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products.[4] It is a major producer of branded oncology medicines[5] cardiology, diabetology and other pharma specialty drugs[6] at affordable prices.[7][8][9][10]

History

Natco Pharma was founded in 1981 by V C Nannapaneni. In 1983, operations commenced at manufacturing facility at Nagarjunasagar. In 1986, the company's chemical division started at Mekaguda near Hyderabad.[citation needed]

In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA,[11] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[6] In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]

In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[12] In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide in the United States.[13] In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]

In 2025, Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company, for approximately US$226 million. The acquisition resulted in the delisting of Adcock Ingram from the Johannesburg Stock Exchange.[15][16][17]

References

  1. ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. ^ "Earnings Presentation - Q4 FY25 & FY25" (PDF). NATCO Pharma Limited. Retrieved 11 July 2025.
  4. ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
  5. ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
  6. ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
  7. ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
  8. ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
  9. ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
  10. ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
  11. ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
  12. ^ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
  13. ^ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
  14. ^ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
  15. ^ "Natco completes 35.75% stake buy in South African firm". Moneycontrol. 12 November 2025. Retrieved 11 March 2026.
  16. ^ "Natco Pharma completes Adcock Ingram delisting from JSE". HDFC Sky. 12 November 2025. Retrieved 11 March 2026.
  17. ^ "Natco Pharma to acquire significant stake in South African firm Adcock Ingram". Economic Times Pharma. 2025. Retrieved 11 March 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.